


38. (Thrice Amended) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis comprising administering to the patient an amount effective for the treatment of seborrheic dermatitis of a composition comprising:


(A) an active component consisting essentially of at least one 1-hydroxy-2-pyridone of formula I, wherein the at least one 1-hydroxy-2-pyridone is present in free form or as a pharmaceutically acceptable salt:



where R^1 , R^2 , and R^3 , which are identical or different, are H or alkyl having 1 to 4 carbon atoms, and R^4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of formula II:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



where:

- X is S or O;
- Y is H, or 1 or 2 identical halogen atoms, or a mixture of 2 different halogen atoms;
- Z is a single bond, or
a linking radical comprising
- (1) O, or
 - (2) S, or
 - (3) -CR₂-, where R is H or (C₁-C₄)-alkyl, or
 - (4) from 2 to 10 carbon atoms linked in the form of a straight or branched chain,
which optionally further comprises one or more of the following:
 - (i) a carbon-carbon double bond, and
 - (ii) O, S, or a mixture thereof, wherein if 2 or more O or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and,
- in any of the foregoing linking radicals, any remaining free valences of the carbon atoms of said linking radical are saturated by H, (C₁-C₄)-alkyl, or a mixture thereof;
- and

Ar is an aromatic ring system having one or two rings, the aromatic ring system being unsubstituted or substituted by one, two, or three radicals, which are identical or different, and are chosen from halogen, methoxy, (C₁-C₄)-alkyl, trifluoromethyl, and trifluoromethoxy; and

(B) at least one surfactant chosen from anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants; and


wherein the composition has a pH ranging from about 4.5 to about 6.5.

39. (Twice Amended) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis comprising administering to the patient an amount effective for the treatment of seborrheic dermatitis of a composition which comprises:


(A) at least one 1-hydroxy-2-pyridone of formula I, wherein the at least one 1-hydroxy-2-pyridone is present in free form or as a pharmaceutically acceptable salt:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



where R^1 , R^2 , and R^3 , which are identical or different, are H or alkyl having 1 to 4 carbon atoms, and R^4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of formula II:



where:

X is S or O;

Y is H, or 1 or 2 identical halogen atoms, or a mixture of 2 different halogen atoms;

Z is a single bond, or

a linking radical comprising

(1) O, or

(2) S, or

(3) $-CR_2-$, where R is H or (C_1-C_4) -alkyl, or

(4) from 2 to 10 carbon atoms linked in the form of a straight or branched chain, which optionally further comprises one or more of the following:

- (i) a carbon-carbon double bond, and
- (ii) O, S, or a mixture thereof, wherein if 2 or more O or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and,

in any of the foregoing linking radicals, any remaining free valences of the carbon atoms of said linking radical are saturated by H, (C₁-C₄)-alkyl, or a mixture thereof;

and

Ar is an aromatic ring system having two rings, the aromatic ring system being unsubstituted or substituted by one, two, or three radicals, which are identical or different, and are chosen from halogen, methoxy, (C₁-C₄)-alkyl, trifluoromethyl, and trifluoromethoxy, and wherein Ar is a bicyclic system derived from biphenyl, diphenylalkane, or diphenyl ether; and


(B) at least one surfactant chosen from anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

53. (New) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis comprising administering to the patient an amount effective for the treatment of seborrheic dermatitis of a composition comprising:


(A) at least one 1-hydroxy-2-pyridone of formula I, wherein the at least one 1-hydroxy-2-pyridone is present in free form or as a pharmaceutically acceptable salt:



where R^1 , R^2 , and R^3 , which are identical or different, are H or alkyl having 1 to 4 carbon atoms, and R^4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of formula II:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



where:

X is S or O;

Y is H, or 1 or 2 identical halogen atoms, or a mixture of 2 different halogen atoms;

Z is a single bond, or

a linking radical comprising

(1) O, or

(2) S, or

(3) $-CR_2-$, where R is H or (C_1-C_4) -alkyl, or

(4) from 2 to 10 carbon atoms linked in the form of a straight or branched chain,

which optionally further comprises one or more of the following:

(i) a carbon-carbon double bond, and

(ii) O, S, or a mixture thereof, wherein if 2 or more O or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and,

in any of the foregoing linking radicals, any remaining free valences of the carbon atoms of said linking radical are saturated by H, (C_1-C_4) -alkyl, or a mixture thereof;

and

- Ar is an aromatic ring system having one or two rings, the aromatic ring system being unsubstituted or substituted by one, two, or three radicals, which are identical or different, and are chosen from halogen, methoxy, (C₁-C₄)-alkyl, trifluoromethyl, and trifluoromethoxy;
- (B) is at least one surfactant chosen from anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants; and
- (C) is at least one keratolytic agent; and
- wherein the composition has a pH ranging from about 4.5 to about 6.5.

54. (New) The method of claim 53, wherein the keratolytic agent is one or more of the agents selected from the group consisting of sulfur, salicylic acid, and enzymes.

55. (New) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis as claimed in claim 53 in which the at least one 1-hydroxy-2-pyridone of formula I comprises a cyclohexyl radical in the R⁴ position.

56. (New) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis as claimed in claim 53 in which the at least one 1-hydroxy-2-pyridone of formula I comprises an octyl radical of the formula -CH₂-CH(CH₃)-CH₂-C(CH₃)₃ in the R⁴ position.

57. (New) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis as claimed in claim 53 in which the pharmaceutical

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

composition comprises 1-hydroxy-4-methyl-6-(4-(4-chlorophenoxy)phenoxy-methyl)-2(1H)pyridone, 1-hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone, or 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1H)pyridone, or a pharmaceutically acceptable salt of any of the foregoing, or a mixture of any of the foregoing.


58. (New) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis as claimed in claim 53 in which the pharmaceutical composition further comprises at least one additional surfactant chosen from anionic, cationic, nonionic, and amphoteric surfactants.

59. (New) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis comprising administering to the patient an amount effective for the treatment of seborrheic dermatitis of a composition which comprises:


(A) at least one 1-hydroxy-2-pyridone of formula I, wherein the at least one 1-hydroxy-2-pyridone is present in free form or as a pharmaceutically acceptable salt:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



where R^1 , R^2 , and R^3 , which are identical or different, are H or alkyl having 1 to 4 carbon atoms, and R^4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of formula II:



where:

X is S or O;

Y is H, or 1 or 2 identical halogen atoms, or a mixture of 2 different halogen atoms;

Z is a single bond, or

a linking radical comprising

(1) O, or

(2) S, or

(3) $-CR_2-$, where R is H or (C_1-C_4) -alkyl, or

(4) from 2 to 10 carbon atoms linked in the form of a straight or branched chain,

which optionally further comprises one or more of the following:

- (i) a carbon-carbon double bond, and
- (ii) O, S, or a mixture thereof, wherein if 2 or more O or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and,

in any of the foregoing linking radicals, any remaining free valences of the carbon atoms of said linking radical are saturated by H, (C₁-C₄)-alkyl, or a mixture thereof;

and

Ar is an aromatic ring system having two rings, the aromatic ring stem being unsubstituted or substituted by one, two, or three radicals, which are identical or different, and are chosen from halogen, methoxy, (C₁-C₄)-alkyl, trifluoromethyl, and trifluoromethoxy, and wherein Ar is a bicyclic system derived from biphenyl, diphenylalkane, or diphenyl ether;

B) is at least one surfactant chosen from anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants; and

(C) is at least one keratolytic agent.

60. (New) The method of claim 59, wherein the keratolytic agent is one or more of the agents selected from the group consisting of sulfur, salicylic acid, and enzymes.

61. (New) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis as claimed in claim 59 in which the at least one 1-hydroxy-2-pyridone of formula I comprises a cyclohexyl radical in the R⁴ position.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

62. (New) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis as claimed in claim 59 in which the at least one 1-hydroxy-2-pyridone of formula I comprises an octyl radical of the formula $-\text{CH}_2\text{-CH}(\text{CH}_3)\text{-CH}_2\text{-C}(\text{CH}_3)_3$ in the R^4 position.

63. (New) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis as claimed in claim 59 in which the pharmaceutical composition comprises 1-hydroxy-4-methyl-6-(4-(4-chlorophenoxy)phenoxyethyl)-2(1H)pyridone, 1-hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone, or 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1H)pyridone, or a pharmaceutically acceptable salt of any of the foregoing, or a mixture of any of the foregoing.


64. (New) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis as claimed in claim 59 in which the pharmaceutical composition further comprises at least one additional surfactant chosen from anionic, cationic, nonionic, and amphoteric surfactants.

65. (New) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis comprising administering to the patient an amount effective for the treatment of seborrheic dermatitis of a composition comprising:


FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

(A) an active component consisting essentially of at least one 1-hydroxy-2-pyridone of formula I, wherein the at least one 1-hydroxy-2-pyridone is present in free form or as a pharmaceutically acceptable salt:



where R^1 , R^2 , and R^3 , which are identical or different, are H or alkyl having 1 to 4 carbon atoms, and R^4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of formula II:



where:

X is S or O;

Y is H, or 1 or 2 identical halogen atoms, or a mixture of 2 different halogen atoms;

Z is a single bond, or

a linking radical comprising

(1) O, or

FINNEGAN,
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

(2) S, or

(3) $-CR_2-$, where R is H or (C_1-C_4) -alkyl, or

(4) from 2 to 10 carbon atoms linked in the form of a straight or branched chain, which optionally further comprises one or more of the following:

(i) a carbon-carbon double bond, and

(ii) O, S, or a mixture thereof, wherein if 2 or more O or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and,

in any of the foregoing linking radicals, any remaining free valences of the carbon atoms of said linking radical are saturated by H, (C_1-C_4) -alkyl, or a mixture thereof;

and

Ar is an aromatic ring system having one or two rings, the aromatic ring system being unsubstituted or substituted by one, two, or three radicals, which are identical or different, and are chosen from halogen, methoxy, (C_1-C_4) -alkyl, trifluoromethyl, and trifluoromethoxy;

(B) is at least one surfactant chosen from anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants;

(C) is lactic acid; and


wherein the composition has a pH ranging from about 4.5 to about 6.5.

66. (New) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis comprising administering to the patient an amount effective for the treatment of seborrheic dermatitis of a composition which comprises:


FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

(A) at least one 1-hydroxy-2-pyridone of formula I, wherein the at least one 1-hydroxy-2-pyridone is present in free form or as a pharmaceutically acceptable salt:



where R^1 , R^2 , and R^3 , which are identical or different, are H or alkyl having 1 to 4 carbon atoms, and R^4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of formula II:



where:

X is S or O;

Y is H, or 1 or 2 identical halogen atoms, or a mixture of 2 different halogen atoms;

Z is a single bond, or
a linking radical comprising

(1) O, or

(2) S, or

(3) $-CR_2-$, where R is H or (C_1-C_4) -alkyl, or

(4) from 2 to 10 carbon atoms linked in the form of a straight or branched chain,

which optionally further comprises one or more of the following:

(i) a carbon-carbon double bond, and

(ii) O, S, or a mixture thereof, wherein if 2 or more O or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and,

in any of the foregoing linking radicals, any remaining free valences of the carbon atoms of said linking radical are saturated by H, (C_1-C_4) -alkyl, or a mixture thereof;

and

Ar is an aromatic ring system having two rings, the aromatic ring system being unsubstituted or substituted by one, two, or three radicals, which are identical or different, and are chosen from halogen, methoxy, (C_1-C_4) -alkyl, trifluoromethyl, and trifluoromethoxy, and wherein Ar is a bicyclic system derived from biphenyl, diphenylalkane, or diphenyl ether;

(B) is at least one surfactant chosen from anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants; and

(C) is lactic acid.

REMARKS

I. Status of the Claims

Claims 38-42, 48, and 53-66 are pending. Claims 38, 39, 53, 59, 65 and 66 are independent. Claims 38 and 39 have been amended, claim 49 has been canceled, and

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com